These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29383359)

  • 21. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
    Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding and discerning interactions of PTP1B allosteric inhibitors: novel insights from molecular dynamics simulations.
    Shinde RN; Sobhia ME
    J Mol Graph Model; 2013 Sep; 45():98-110. PubMed ID: 24012873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
    af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
    ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: wild type and mutant (L1196M) active compounds with unique binding mode.
    Gummadi VR; Rajagopalan S; Looi CY; Paydar M; Renukappa GA; Ainan BR; Krishnamurthy NR; Panigrahi SK; Mahasweta K; Raghuramachandran S; Rajappa M; Ramanathan A; Lakshminarasimhan A; Ramachandra M; Wong PF; Mustafa MR; Nanduri S; Hosahalli S
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4911-8. PubMed ID: 23880539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
    Ai X; Shen S; Shen L; Lu S
    Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
    Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
    J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
    Shen M; Zhou S; Li Y; Li D; Hou T
    Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
    Chen SF; Cao Y; Han S; Chen JZ
    J Mol Graph Model; 2014 Mar; 48():36-46. PubMed ID: 24374242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
    Wang JL; Cheng LP; Wang TC; Deng W; Wu FH
    J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
    Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
    Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
    Zhan JY; Zhang JL; Wang Y; Li Y; Zhang HX; Zheng QC
    J Biomol Struct Dyn; 2016 Nov; 34(11):2351-66. PubMed ID: 26549408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors.
    Araujo SC; Maltarollo VG; Almeida MO; Ferreira LLG; Andricopulo AD; Honorio KM
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases.
    Verma J; Vashisth H
    Proteins; 2024 Aug; 92(8):905-922. PubMed ID: 38506327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.
    Almeida MO; Costa CHS; Gomes GC; Lameira J; Alves CN; Honorio KM
    J Biomol Struct Dyn; 2018 Nov; 36(15):4010-4022. PubMed ID: 29132261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
    Chen X; Li C; Wang D; Chen Y; Zhang N
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of protein flexibility in ranking ERK2 Type I
    Niu Y; Yao X; Ji H
    RSC Adv; 2019 Apr; 9(22):12441-12454. PubMed ID: 35515820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
    Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
    Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.